Alzheimer’s disease affects over five million people in the United States and could be as high as 16 million by 2050. The economic impact of this disease is daunting with current estimates being above $250 billion dollars per year. It is the sixth leading cause in the United States and robs people of their essence. To date, efforts to address not only the symptoms but the root cause of Alzheimer’s disease have been in vain with countless failures in the clinic.
There has been considerable research related to impaired glucose metabolism in the brain leading to Alzheimer’s disease symptoms and progression. Impel is proud to be partnering with the NIH in two separate clinical trials evaluating the use of intranasal insulin to address some of the proposed causes and clinical outcomes of mild cognitive impairment and Alzheimer’s disease. We anticipate these NIH studies will report topline clinical data in 2018 and we are preparing our INP102 program, insulin in our POD™ technology, for further clinical development.